Year Ended October 31,
2001 2000 1999
In thousands, except share and per share data
Revenues:
  Oxyglobin   $ 3,482     $ 3,058     $ 2,749  
  Other     7       5       117  
Total revenues     3,489       3,063       2,866  
Cost of revenues     3,665       4,778       6,814  
Gross profit (loss)     (176 )     (1,715 )     (3,948 )
Operating expenses:
  Research and development     34,609       26,378       24,166  
  Sales and marketing     2,807       2,463       2,922  
  General and administration     15,365       9,878       5,266  
    Total operating expenses     52,781       38,719       32,354  
Loss from operations     (52,957 )     (40,434 )     (36,302 )
Other income (expense):
  Interest income     3,609       4,424       1,041  
  Interest expense     (71 )     (68 )     (469 )
  Other                 200  
    Total other income, net     3,538       4,356       772  
Net loss     (49,419 )     (36,078 )     (35,530 )
Stock dividends on preferred stock                 (17,915 )
Net loss applicable to common stockholders   $ (49,419 )   $ (36,078 )   $ (53,445 )
Per share data:
  Basic net loss per common share   $ (1.97 )   $ (1.51 )   $ (3.61 )
  Weighted-average shares used in computing basic net loss
    per common share
    25,066,132       23,947,251       14,813,045  
Pro forma (unaudited):
  Pro forma basic net loss per common share                   $ (2.62 )
  Weighted-average shares used in computing pro
    forma basic net loss per common share
                    20,368,860  

See accompanying notes.